![EverImmune appoints Prof. Laurence Zitvogel as president of scientific advisory board](https://ala.associates/wp-content/uploads/2022/11/Pr-Laurence-Zitvogel-everImmune-1080x675.jpg)
![EverImmune appoints Prof. Laurence Zitvogel as president of scientific advisory board](https://ala.associates/wp-content/uploads/2022/11/Pr-Laurence-Zitvogel-everImmune-1080x675.jpg)
![Enalees opens first subsidiary in the UK](https://ala.associates/wp-content/uploads/2022/11/Enalees-lab-1080x675.jpg)
Enalees opens first subsidiary in the UK
![Oncovita presents preclinical data on its promising MVdeltaC oncolytic vaccine at SITC Annual Meeting 2022](https://ala.associates/wp-content/uploads/2022/11/Jean-Francois-Le-Bigot-CEO-Oncovita-e1667383832926-714x675.jpg)
Oncovita presents preclinical data on its promising MVdeltaC oncolytic vaccine at SITC Annual Meeting 2022
![Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress](https://ala.associates/wp-content/uploads/2022/10/Arnaud-Foussat-CEO-Alderaan-Biotechnology-1080x675.png)
Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress
![Positive results from AELIX’ HIV therapeutic vaccine clinical study published in Nature Medicine](https://ala.associates/wp-content/uploads/2022/10/MG_6826-1080x675.jpg)
Positive results from AELIX’ HIV therapeutic vaccine clinical study published in Nature Medicine
![Enalees receives €500,000 subsidy](https://ala.associates/wp-content/uploads/2022/10/Laurent-thiery-Enalees-scaled-e1666597643904-1080x675.jpg)
Enalees receives €500,000 subsidy
![ABL and Imugene partner to advance oncolytic virus candidate towards later phase clinical trials](https://ala.associates/wp-content/uploads/2022/10/ABL-Imugene-ALA-website-1-1080x675.png)
ABL and Imugene partner to advance oncolytic virus candidate towards later phase clinical trials
![Bioxodes appoints Marc Dechamps as new CEO](https://ala.associates/wp-content/uploads/2022/10/MD-photo-full-2-1080x675.jpeg)
Bioxodes appoints Marc Dechamps as new CEO
![L’écosystème de santé Belge montre une grande implication pour l’évènement européen HealthTech Innovation Days, les 13 à 14 octobre à Paris](https://ala.associates/wp-content/uploads/2022/10/Logo2-HTID--1080x675.png)
L’écosystème de santé Belge montre une grande implication pour l’évènement européen HealthTech Innovation Days, les 13 à 14 octobre à Paris
![Immunotherapy: Tollys presents new data at OTS 2022, demonstrating anti-tumor activity of TL-532](https://ala.associates/wp-content/uploads/2022/09/Marc-Bonnin-2-e1663749178143.png)